Publications: Mrs Rhiannon Roberts
Zardab M, Balarajah V, Banerjee A, Stasinos K, Saad A, Imrali A, Hughes C, Roberts R et al.
(
2022
)
.
Differentiating Ductal Adenocarcinoma of the Pancreas from Benign Conditions Using Routine Health Records: A Prospective Case-Control Study
.
Cancers
vol.
15
,
(
1
)
Debernardi S, O’Brien H, Algahmdi AS, Malats N, Stewart GD, Plješa-Ercegovac M, Costello E, Greenhalf W et al.
(
2020
)
.
A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case–control study
.
PLOS Medicine
vol.
17
,
(
12
)
Kocher HM, Basu B, Froeling FE, Sarker D, Slater S, Carlin D, deSouza NM, De Paepe KN et al.
(
2020
)
.
STARPAC clinical trial
.
Pancreatology
vol.
20
,
(
8
)
Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, deSouza NM, De Paepe KN et al.
(
2020
)
.
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer
.
Nature Communications
vol.
11
,
(
1
)
Schilling K, Larner F, Saad A, Roberts R, Kocher HM, Blyuss O, Halliday AN, Crnogorac-Jurcevic T
(
2020
)
.
Urine metallomics signature as an indicator of pancreatic cancer
.
Metallomics: integrated biometal science
Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, Coetzee C, de Souza N et al.
(
2019
)
.
700P STAR-PAC: Phase I clinical trial repurposing all trans retinoic acid (ATRA) as stromal targeting agent in a novel drug combination for pancreatic cancer
.
Annals of Oncology
vol.
30
,
Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, Coetzee C, de Souza N et al.
(
2019
)
.
STAR-PAC: Phase I clinical trial repurposing all trans retinoic acid (ATRA) as stromal targeting agent in a novel drug combination for pancreatic cancer
.
ANNALS OF ONCOLOGY
.
vol.
30
,